Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Theravance Biopharma's interest expense for the
three
months ended in Mar. 2026 was € 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was €-1.56 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Theravance Biopharma's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as
GuruFocus does not calculate Theravance Biopharma's interest coverage with the available data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Theravance Biopharma Interest Expense Historical Data
* Premium members only.
The historical data trend for Theravance Biopharma's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.56 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theravance Biopharma (FRA:0TB) has a Interest Expense of €-1.56 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Theravance Biopharma and its competitors.
Is Theravance Biopharma's Interest Expense too high?
Theravance Biopharma's current Interest Expense is €-1.56 Mil. Overall, Theravance Biopharma has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Theravance Biopharma's Interest Expense compare to ABUS and SANA?
Theravance Biopharma's Interest Expense of €-1.56 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Theravance Biopharma and its competitors. Theravance Biopharma's current Interest Expense is €-1.56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theravance Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Theravance Biopharma (FRA:0TB) is currently considered Modestly Undervalued. The stock's GF Value™ is €16.18, compared to a current price of €14.60 — trading 9.8% below its estimated fair value. The current Interest Expense is €-1.56 Mil. Theravance Biopharma's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Theravance Biopharma (FRA:0TB), the current Interest Expense is €-1.56 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Theravance Biopharma (FRA:0TB) Overvalued in 2026?
Based on GuruFocus' analysis, Theravance Biopharma stock appears to be undervalued.
The current stock price of €14.60 is trading 9.8% below its estimated GF Value™ of €16.18.
GuruFocus considers Theravance Biopharma to be Modestly Undervalued.
Key valuation signals for FRA:0TB:
Interest Expense: €-1.56 Mil
GF Value™: €16.18 vs. price of €14.60 (9.8% below fair value)
No single metric tells the full story. See the FRA:0TB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
72GF Score
Get the complete analysis for FRA:0TB
Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0TB has been successfully added to your 
